Siekesys plans to change brokers and attempt a third IPO: previously attempted the STAR Market and Shenzhen Main Board without success, with China National Pharmaceutical Group as a major client

Crypto Finance Wu Wenting Recently, Seeksys Biotechnology Co., Ltd. (hereinafter referred to as “Seeksys”) disclosed the completion report of its IPO guidance work, with the guiding institution being Everbright Securities Co., Ltd. (hereinafter referred to as “Everbright Securities”).

It is understood that Seeksys launched its IPO on October 20, 2025, and Everbright Securities carried out one phase of guidance.

Seeksys mainly engages in the research, production, and sales of implantable biological material medical devices. Represented by composite microporous polysaccharide hemostatic powder and surgical anti-adhesion liquid, the company has strong technological leadership and research advantages in the fields of hemostasis and surgical anti-adhesion.

Notably, Seeksys previously attempted to list on the STAR Market and the Shenzhen Main Board but was unsuccessful. Its STAR Market IPO application was accepted on June 30, 2020, but was withdrawn by the company and sponsor Haitong Securities, leading to the termination of the IPO on December 8, 2020.

Its Shenzhen Main Board IPO application was accepted on February 23, 2023, but was also withdrawn by the company and Haitong Securities, with the IPO terminated on January 7, 2025.

According to the prospectus, from 2021 to 2023, China National Pharmaceutical Group Co., Ltd. was the company’s largest customer, accounting for 13.29%, 11.08%, and 8.66% of sales, respectively.

Related companies: China National Pharmaceutical Group HK01099, Seeksys